ACCUNEB
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ACCUNEB (ACCUNEB).
Relaxes bronchial smooth muscle by stimulating beta2-adrenergic receptors, increasing cyclic AMP, and inhibiting mediator release from mast cells.
| Metabolism | Metabolized primarily by catechol-O-methyltransferase (COMT) and to a lesser extent by sulfatase enzymes in the gastrointestinal tract. |
| Excretion | Renal: ~70% as unchanged drug and active metabolite (N-acetylprocainamide) within 24 hours; biliary/fecal: minimal (<5%) |
| Half-life | 2-5 hours (procainamide); 6-8 hours (N-acetylprocainamide); prolonged in renal impairment (up to 20 hours) |
| Protein binding | 15-20% bound to albumin and alpha-1-acid glycoprotein |
| Volume of Distribution | 1.5-2.5 L/kg; distributes widely into tissues with high affinity for cardiac tissue |
| Bioavailability | Oral immediate-release: 75-95%; IM: 100%; IV: 100% |
| Onset of Action | IM: 10-30 min; IV: 5-10 min; Oral: 30-60 min |
| Duration of Action | 3-4 hours (immediate-release); 6-12 hours (extended-release); antiarrhythmic effect persists as long as therapeutic serum levels maintained |
Inhaled: Nebulized solution 0.63 mg or 1.25 mg three times daily every 6-8 hours; or 0.63 mg twice daily in patients with asthma. Alternatively, 2.5 mg three times daily via nebulization.
| Dosage form | SOLUTION |
| Renal impairment | No specific dose adjustment required; drug undergoes minimal renal excretion. Use with caution in severe renal impairment (CrCl <30 mL/min) due to potential for systemic accumulation. |
| Liver impairment | No specific dose adjustment for Child-Pugh Class A or B. For Child-Pugh Class C, consider dose reduction by 50% due to reduced clearance. |
| Pediatric use | Children 2-12 years: Nebulized solution 0.31 mg, 0.63 mg, or 1.25 mg three times daily every 6-8 hours based on severity. For children ≥12 years, same as adult dosing. |
| Geriatric use | Start at lower end of dosing range (0.63 mg three times daily) due to potential age-related renal impairment and increased sensitivity to beta-agonists. Monitor for tachycardia and tremors. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ACCUNEB (ACCUNEB).
| Breastfeeding | Levalbuterol is excreted into breast milk in small amounts. The M/P ratio is unknown. Caution is advised; monitor infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability). |
| Teratogenic Risk | ACCUNEB (levalbuterol) is a beta-2 adrenergic agonist. Based on animal studies and human data, there is no evidence of teratogenicity. However, during the second and third trimesters, beta-agonists may cause fetal tachycardia, hypoglycemia, and hypocalcemia. Use only if potential benefit justifies risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to levalbuterol or any component of the product"]
| Precautions | ["Paradoxical bronchospasm","Cardiovascular effects including increased heart rate and blood pressure","Hypokalemia","Immediate hypersensitivity reactions"] |
| Food/Dietary | No specific food interactions. Avoid caffeine and other stimulants as they may increase side effects like nervousness and rapid heartbeat. |
| Clinical Pearls | ACCUNEB (levalbuterol) is the R-isomer of albuterol, designed to reduce beta-adrenergic side effects. It is preferred in patients with tachycardia or sensitivity to beta-agonists. Monitor for paradoxical bronchospasm; discontinue immediately if occurs. Nebulized solution should be used with a jet nebulizer connected to an air compressor. Not for acute deterioration unless patient is already on regular therapy. |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal heart rate, blood pressure, and serum potassium. Fetal monitoring may be considered for signs of tachycardia or distress in cases of high-dose or prolonged use. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Human data are limited. |
| Patient Advice | Use only as prescribed; do not increase dose or frequency without consulting your doctor. · Shake the nebulizer solution well before use. Do not mix with other medications unless instructed. · If you experience worsening breathing, chest tightness, or hives, stop the medication and seek medical help immediately. · Rinse mouth with water after each use to prevent throat irritation and thrush. · Store at room temperature away from light and moisture. Do not freeze. |